• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.逆转录酶抑制剂的分子机制与病毒耐药性的进化。
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20057-62. doi: 10.1073/pnas.1010246107. Epub 2010 Oct 28.
2
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.携带可导致非核苷类逆转录酶和整合酶链转移抑制剂耐药突变的 HIV-1 中病毒适应性和药物敏感性的改变。
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
3
Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.分子动力学方法估算 HIV-1 整合酶抑制剂的结合能,并与体外活性相关联。
Antimicrob Agents Chemother. 2012 Jan;56(1):411-9. doi: 10.1128/AAC.05292-11. Epub 2011 Oct 28.
4
Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.对拉替拉韦的耐药性突出了整合酶 148 密码子的突变,从而赋予了对第二代 HIV-1 整合酶抑制剂的交叉耐药性。
Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12.
5
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.与雷特格韦治疗失败相关的突变在体外会影响整合酶对该抑制剂的敏感性。
Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28.
6
MK-0536 inhibits HIV-1 integrases resistant to raltegravir.MK-0536 抑制对拉替拉韦耐药的 HIV-1 整合酶。
Antimicrob Agents Chemother. 2011 Nov;55(11):5127-33. doi: 10.1128/AAC.05288-11. Epub 2011 Aug 29.
7
Impact of resistance mutations on inhibitor binding to HIV-1 integrase.耐药性突变对抑制剂与HIV-1整合酶结合的影响。
J Chem Inf Model. 2013 Dec 23;53(12):3297-307. doi: 10.1021/ci400537n. Epub 2013 Nov 21.
8
Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.特写:HIV/SIV 整合酶三聚体结构揭示整合酶抑制剂结合和病毒逃逸机制的新机制
FEBS J. 2021 Jan;288(2):427-433. doi: 10.1111/febs.15438. Epub 2020 Jun 22.
9
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.来自对拉替拉韦耐药患者的HIV整合酶中的G140S突变挽救了因耐药性Q148H突变导致的催化缺陷。
Nucleic Acids Res. 2009 Mar;37(4):1193-201. doi: 10.1093/nar/gkn1050. Epub 2009 Jan 7.
10
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.雷特格韦与埃替格韦对HIV-1整合酶催化反应及一系列耐药整合酶突变体的比较
Biochemistry. 2008 Sep 9;47(36):9345-54. doi: 10.1021/bi800791q. Epub 2008 Aug 15.

引用本文的文献

1
VCY mediates inhibition of PFV replication via interaction with the transcription activator Tas.VCY通过与转录激活因子Tas相互作用介导对PFV复制的抑制。
J Virol. 2025 Jul 22;99(7):e0016625. doi: 10.1128/jvi.00166-25. Epub 2025 Jun 3.
2
SAP30 deacetylates the Tas protein to inhibit PFV replication.SAP30使Tas蛋白脱乙酰化以抑制PFV复制。
Cell Biosci. 2025 Apr 24;15(1):53. doi: 10.1186/s13578-025-01400-2.
3
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3',5'-bisphosphate as a potent enzyme inhibitor.将外切核糖核酸酶XRN1鉴定为癌症靶点并确定3',5'-二磷酸腺苷为一种有效的酶抑制剂。
Commun Biol. 2025 Apr 9;8(1):589. doi: 10.1038/s42003-025-08005-y.
4
Noncanonical HIV drug resistance mutations: need to close existing gaps.非典型HIV耐药性突变:需要填补现有差距。
AIDS. 2025 Jun 1;39(7):781-787. doi: 10.1097/QAD.0000000000004170. Epub 2025 Mar 17.
5
Quinolinonyl Derivatives as Dual Inhibitors of the HIV-1 Integrase Catalytic Site and Integrase-RNA interactions.喹啉基衍生物作为HIV-1整合酶催化位点和整合酶-RNA相互作用的双重抑制剂
ACS Med Chem Lett. 2024 Aug 5;15(9):1533-1540. doi: 10.1021/acsmedchemlett.4c00268. eCollection 2024 Sep 12.
6
Brief Histories of Retroviral Integration Research and Associated International Conferences.逆转录病毒整合研究及相关国际会议简史
Viruses. 2024 Apr 13;16(4):604. doi: 10.3390/v16040604.
7
The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.人类免疫缺陷病毒治疗背景下的抗逆转录病毒药物耐药现象:动态且不断演变的主题。
Biomedicines. 2024 Apr 20;12(4):915. doi: 10.3390/biomedicines12040915.
8
Kinetic coevolutionary models predict the temporal emergence of HIV-1 resistance mutations under drug selection pressure.动力学共进化模型预测了 HIV-1 耐药突变在药物选择压力下的时间出现。
Proc Natl Acad Sci U S A. 2024 Apr 9;121(15):e2316662121. doi: 10.1073/pnas.2316662121. Epub 2024 Apr 1.
9
Elucidating the Molecular Determinants of the Binding Modes of a Third-Generation HIV-1 Integrase Strand Transfer Inhibitor: The Importance of Side Chain and Solvent Reorganization.阐明第三代 HIV-1 整合酶链转移抑制剂结合模式的分子决定因素:侧链和溶剂重排的重要性。
Viruses. 2024 Jan 2;16(1):0. doi: 10.3390/v16010076.
10
Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity.携带1,3,4-恶二唑环的拉替拉韦在pH值变化时转化为水解产物会降低其抗病毒活性。
PNAS Nexus. 2023 Dec 18;3(1):pgad446. doi: 10.1093/pnasnexus/pgad446. eCollection 2024 Jan.

本文引用的文献

1
The mechanism of retroviral integration from X-ray structures of its key intermediates.逆转录病毒整合的机制来自其关键中间体的 X 射线结构。
Nature. 2010 Nov 11;468(7321):326-9. doi: 10.1038/nature09517.
2
Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.不同结构类型的整合酶链转移抑制剂对 HIV-1 突触复合物的物理捕获。
Biochemistry. 2010 Sep 28;49(38):8376-87. doi: 10.1021/bi100514s.
3
Structure-based modeling of the functional HIV-1 intasome and its inhibition.基于结构的功能性 HIV-1 整合酶三聚体模型及其抑制作用。
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15910-5. doi: 10.1073/pnas.1002346107. Epub 2010 Aug 23.
4
Resistance to integrase inhibitors.对整合酶抑制剂的耐药性。
Viruses. 2010 Jun 25;2(7):1347-66. doi: 10.3390/v2071347.
5
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.鉴定新型突变导致对第二代 HIV-1 整合酶抑制剂 MK-2048 的耐药性。
J Virol. 2010 Sep;84(18):9210-6. doi: 10.1128/JVI.01164-10. Epub 2010 Jul 7.
6
Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited.二羟嘧啶类 HIV 整合酶抑制剂的支架重排:对接模型再探讨。
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3275-9. doi: 10.1016/j.bmcl.2010.04.048. Epub 2010 Apr 21.
7
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.体外使用拉替拉韦选择的原发性突变可导致对第一代整合酶抑制剂的敏感性发生大幅度变化,但对具有第二代耐药谱的抑制剂仅有较小的变化倍数。
Virology. 2010 Jul 5;402(2):338-46. doi: 10.1016/j.virol.2010.03.034. Epub 2010 Apr 24.
8
Nucleoprotein intermediates in HIV-1 DNA integration visualized by atomic force microscopy.原子力显微镜观察到的 HIV-1 DNA 整合中的核蛋白中间体。
J Mol Biol. 2010 Jun 11;399(3):491-500. doi: 10.1016/j.jmb.2010.04.026. Epub 2010 Apr 21.
9
Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.抗雷特格韦的 HIV-1 整合酶柔性环突变体的生化和药理学分析。
Biochemistry. 2010 May 4;49(17):3715-22. doi: 10.1021/bi100130f.
10
Retroviral intasome assembly and inhibition of DNA strand transfer.逆转录病毒内切体组装和 DNA 链转移抑制。
Nature. 2010 Mar 11;464(7286):232-6. doi: 10.1038/nature08784. Epub 2010 Jan 31.

逆转录酶抑制剂的分子机制与病毒耐药性的进化。

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.

机构信息

Division of Infectious Diseases, Imperial College London, London W2 1PG, United Kingdom.

出版信息

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20057-62. doi: 10.1073/pnas.1010246107. Epub 2010 Oct 28.

DOI:10.1073/pnas.1010246107
PMID:21030679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2993412/
Abstract

The development of HIV integrase (IN) strand transfer inhibitors (INSTIs) and our understanding of viral resistance to these molecules have been hampered by a paucity of available structural data. We recently reported cocrystal structures of the prototype foamy virus (PFV) intasome with raltegravir and elvitegravir, establishing the general INSTI binding mode. We now present an expanded set of cocrystal structures containing PFV intasomes complexed with first- and second-generation INSTIs at resolutions of up to 2.5 Å. Importantly, the improved resolution allowed us to refine the complete coordination spheres of the catalytic metal cations within the INSTI-bound intasome active site. We show that like the Q148H/G140S and N155H HIV-1 IN variants, the analogous S217H and N224H PFV INs display reduced sensitivity to raltegravir in vitro. Crystal structures of the mutant PFV intasomes in INSTI-free and -bound forms revealed that the amino acid substitutions necessitate considerable conformational rearrangements within the IN active site to accommodate an INSTI, thus explaining their adverse effects on raltegravir antiviral activity. Furthermore, our structures predict physical proximity and an interaction between HIV-1 IN mutant residues His148 and Ser/Ala140, rationalizing the coevolution of Q148H and G140S/A mutations in drug-resistant viral strains.

摘要

HIV 整合酶(IN)链转移抑制剂(INSTIs)的发展以及我们对这些分子的病毒耐药性的理解受到可用结构数据不足的阻碍。我们最近报道了原型泡沫病毒(PFV)整合酶与雷特格韦和艾维雷韦的共晶结构,确立了一般的 INSTI 结合模式。我们现在提供了一组扩展的共晶结构,其中包含与第一代和第二代 INSTIs 结合的 PFV 整合酶,分辨率高达 2.5 Å。重要的是,分辨率的提高使我们能够细化 INSTI 结合整合酶活性位点内催化金属阳离子的完整配位球。我们表明,与 Q148H/G140S 和 N155H HIV-1 IN 变体一样,类似的 S217H 和 N224H PFV IN 对 raltegravir 的体外敏感性降低。无 INSTI 和有 INSTI 结合形式的突变 PFV 整合酶的晶体结构表明,氨基酸取代需要在 IN 活性位点内进行相当大的构象重排以容纳 INSTI,从而解释了它们对 raltegravir 抗病毒活性的不利影响。此外,我们的结构预测了 HIV-1 IN 突变残基 His148 和 Ser/Ala140 之间的物理接近性和相互作用,合理地解释了耐药病毒株中 Q148H 和 G140S/A 突变的共同进化。